Drugs / Ultra-fluid lipiodol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02971345 Background | Jan 2017 → Oct 2020 | hepatocellular carcinoma, portal vein thrombosis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02630108 Background | Dec 2015 → Dec 2017 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultra-fluid lipiodol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02630108 ↗ |